Full Text View
Tabular View
No Study Results Posted
Related Studies
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour Application
This study is currently recruiting participants.
Study NCT00466570   Information provided by Stanford University
First Received: April 25, 2007   Last Updated: April 26, 2007   History of Changes

April 25, 2007
April 26, 2007
April 2007
 
Antibiotic killing of conjunctival bacterial flora 1 hour after application
Same as current
Complete list of historical versions of study NCT00466570 on ClinicalTrials.gov Archive Site
 
 
 
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour Application
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour

Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

 
 
Interventional
Prevention, Randomized, Single Blind, Active Control, Factorial Assignment, Efficacy Study
Conjunctical Flora
Drug: gatifloxacin, moxifloxacin
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
100
 
 

Inclusion Criteria:

  • Age- older than 50 years of age
  • Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

  • Systemic or topical antibiotic treatment within 30 days
  • Use of systemic or topical steroids
  • Active ocular infection
  • Ocular surgery in the past 6 months
  • Allergy to fluoroquinolones
Both
50 Years and older
No
Contact: Miri Englander, BA 650 804 8408 MiriMD@Stanford.edu
United States
 
NCT00466570
 
8924
Stanford University
 
Principal Investigator: Christopher Ta, MD Stanford University
Stanford University
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP